New York State Common Retirement Fund raised its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 21.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 154,751 shares of the consumer goods maker’s stock after purchasing an additional 27,124 shares during the quarter. New York State Common Retirement Fund’s holdings in Cryoport were worth $10,292,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. purchased a new position in Cryoport during the 3rd quarter valued at approximately $59,000. FinTrust Capital Advisors LLC grew its holdings in Cryoport by 199.6% during the 2nd quarter. FinTrust Capital Advisors LLC now owns 1,504 shares of the consumer goods maker’s stock valued at $95,000 after buying an additional 1,002 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Cryoport by 500.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,400 shares of the consumer goods maker’s stock valued at $151,000 after buying an additional 2,000 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in Cryoport during the 2nd quarter valued at approximately $157,000. Finally, GWM Advisors LLC purchased a new position in Cryoport during the 3rd quarter valued at approximately $200,000.
Shares of CYRX stock opened at $59.17 on Monday. Cryoport, Inc. has a 52-week low of $43.46 and a 52-week high of $86.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.66 and a current ratio of 9.99. The firm has a market capitalization of $2.74 billion, a P/E ratio of -33.06 and a beta of 0.95. The stock has a 50 day moving average price of $69.06 and a 200 day moving average price of $65.26.
Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Thursday, November 4th. The consumer goods maker reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). Cryoport had a positive return on equity of 2.67% and a negative net margin of 12.57%. The business had revenue of $56.69 million for the quarter, compared to the consensus estimate of $54.44 million. During the same period in the prior year, the business posted ($0.29) earnings per share. Cryoport’s revenue was up 407.5% on a year-over-year basis. As a group, sell-side analysts forecast that Cryoport, Inc. will post -0.63 EPS for the current year.
CYRX has been the subject of several research analyst reports. B. Riley restated a “buy” rating on shares of Cryoport in a report on Thursday, November 11th. KeyCorp raised their price objective on Cryoport from $75.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, November 5th. Needham & Company LLC raised their price objective on Cryoport from $79.00 to $93.00 and gave the company a “buy” rating in a research note on Friday, November 5th. Roth Capital lowered Cryoport from a “buy” rating to a “neutral” rating and raised their price objective for the company from $78.00 to $90.00 in a research note on Friday, November 5th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Cryoport from a “sell” rating to a “hold” rating in a research note on Tuesday, November 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $84.75.
In other Cryoport news, Director Daniel M. Hancock sold 11,217 shares of Cryoport stock in a transaction on Thursday, October 21st. The stock was sold at an average price of $75.74, for a total transaction of $849,575.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert Stefanovich sold 49,918 shares of Cryoport stock in a transaction on Thursday, October 14th. The shares were sold at an average price of $67.70, for a total value of $3,379,448.60. The disclosure for this sale can be found here. Insiders have sold a total of 691,635 shares of company stock valued at $51,649,822 over the last three months. 10.90% of the stock is owned by corporate insiders.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Recommended Story: Gap Down Stocks
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc. (NASDAQ:CYRX).
Want More Great Investing Ideas?